Key Publications

Past Five Years

Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Cosgun KN, Sadras T, Lee J, Salgia R, Ernst T, Hochhaus A, Jumaa H, Jiang X, Weinstock DM, Graeber TG & Müschen M. B cell-specific diversion of glucose carbon utilization reveals a unique vulnerability in B cell malignancies. Cell 173: March 15 (2018)
http://www.cell.com/cell/fulltext/S0092-8674(18)30225-3

Müschen M. Autoimmunity checkpoints as therapeutic targets in B cell malignancies. Nature Rev Cancer 2018; 18: doi: 10.1038/nrc.2017.111
https://www.nature.com/articles/nrc.2017.111

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Hochhaus A, Kornblau SM, Konopleva M, Cazzaniga G, Milne TA, Koeffler HP, Ross TS, Sanchez-Garcia S, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG & Müschen M. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature 542: 479-483 (2017)
http://stke.sciencemag.org/content/10/468/eaan0507
http://www.nature.com/nri/journal/v17/n3/full/nri.2017.17.html

Shojaee S, Chan LN, Buchner B, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, Zhang N, Dühren von Minden M, Ernst E, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H & Müschen M. PTEN is essential for oncogenic transformation of pre-B cells. Nature Medicine 22: 379-387 (2016)
http://www.nature.com/nm/journal/v22/n4/pdf/nm.4083.pdf
http://stke.sciencemag.org/content/9/423/ec84
http://www.nature.com/nrc/journal/vaop/ncurrent/pdf/nrc.2016.39.pdf

Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, Lieber MR, Greaves MF & Müschen M. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nature Immunol. 16: 766-774 (2016)
http://www.nature.com/nrc/journal/v16/n6/full/nrc.2016.40.html

Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA & Müschen M. Signaling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 521:357-361 (2015).
http://cancerdiscovery.aacrjournals.org/content/5/5/464.2
https://f1000.com/prime/725402302#abstract

Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, Koeffler HP, Willman CL, Hunger SP, Melnick A, Kornblau SM, & Müschen M. Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell. 28:114-128 (2015)
http://cancerdiscovery.aacrjournals.org/content/early/2015/06/24/2159-8290.CD-RW2015-117

Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Paietta E, Melnick A, Hunger SP, Tyner JW, Loh ML, Roeder RG, Druker BJ, Burger JA, Milne TA, Chang BH & Müschen M. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-425 (2015)
http://cancerdiscovery.aacrjournals.org/content/5/5/OF15
http://www.sciencedirect.com/science/article/pii/S1535610815000628

Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, Ng C, Titz B, Hurtz C, Sadiyah MF, Nowak D, Thoennissen GB, Rand V, Graeber TG, Koeffler HP, Carroll WL, Willman CL, Hall AG, Igarashi K, Melnick A & Müschen M. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine. 19: 1014-1022 (2013)
http://www.cell.com/cancer-cell/pdf/S1535-6108(13)00363-2.pdf
https://f1000.com/prime/718030862

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, & Müschen M. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 485: 384-388 (2012)
http://jem.rupress.org/content/208/11/2155
http://www.sciencedirect.com/science/article/pii/S1535610811002339
https://f1000.com/prime/10707956
http://www.nature.com/nrc/journal/v11/n7/full/nrc3099.html